Gastrointestinal Endoscopy in Patients Receiving Antithrombotic Therapy

Authors

  • Supriadi Supriadi Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga/Dr Soetomo General Hospital, Surabaya
  • Titong Sugihartono Division of Gastroentero-hepatology, Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga/Dr Soetomo General Hospital, Surabaya

DOI:

https://doi.org/10.24871/2222021134-139

Keywords:

Gastrointestinal Endoscopy, antithrombotic, antiplatelet, anticoagulant, thromboembolism

Abstract

Gastrointestinal endoscopy is used as a diagnostic and therapeutic tool. Patients receiving antithrombotic agents are at higher risk for bleeding in this procedure. Regarding its thromboembolic versus bleeding risk, physicians should consider to adjust antithrombotic therapy in patients undergoing gastrointestinal endoscopy. Some important factors including the urgency of the procedure, bleeding risk from the procedure and antithrombotic itself, and the risk of thromboembolic events during endoscopy if antithrombotic is to be stopped need to be considered wisely. Based on recommendations of ASGE, ESGE, and BSG, endoscopic procedures were divided based on the level of emergency, namely elective and urgent. In elective endoscopy with high risk of bleeding and thromboembolism, antithrombotic therapy is given in the minimum duration required and then discontinued before the procedure. In elective endoscopy with low risk of bleeding and thromboembolism, antithrombotic can be continued as usual. In urgent endoscopy due to gastrointestinal bleeding, all antithrombotic should be discontinued. Antithrombotic can be restarted within 48 hours after the procedure if no bleeding is evident

Downloads

Published

2021-09-27

How to Cite

Supriadi, S., & Sugihartono, T. (2021). Gastrointestinal Endoscopy in Patients Receiving Antithrombotic Therapy. The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy, 22(2), 134–139. https://doi.org/10.24871/2222021134-139

Issue

Vol. 22 No. 2 (2021): VOLUME 22, NUMBER 2, August 2021

Section

Review Article

License

Authors who publish with this journal agree to the following terms:

a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).